# GSK plc 28.4% potential upside indicated by Citigroup

- Link: https://www.directorstalkinterviews.com/gsk-plc-28-4-potential-upside-indicated-by-citigroup/4121165249
- Published: 2024-07-16T13:07:15+01:00
- Author: Charlotte Edwards

**[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)**
with ticker ([LON:GSK](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l))
now has a potential upside of 28.4% according to Citigroup.
GSK.LCitigroup set a
target price of 1,900 GBX for the company, which when compared to the GSK plc share
price of 1,480 GBX at opening today (16/07/2024) indicates a potential upside of
28.4%. Trading has ranged between 1,314 (52 week low) and 1,824 (52 week high) with
an average of 8,017,236 shares exchanging hands daily. The market capitalisation
at the time of writing is £61,844,056,480.GSK plc is a global biopharma company.
The Company’s segments include Commercial Operations and Research and Development.
It develops cancer medicines for patients, including ovarian cancer, endometrial
cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines,
and general medicine. It is also focused on addressing the unmet treatment needs
of patients with respiratory and inflammatory conditions. Its vaccine portfolio 
includes over 20 vaccines that help to protect people from a range of diseases and
infections, including meningitis, shingles and flu, among others. Its specialty 
medicines are also engaged in developing medicines for respiratory disease and HIV.
Its general medicines include inhaled medicines for asthma and chronic obstructive
pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing
oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease 
as well as other therapeutic areas beyond liver disease.

Share on: